Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $9.33 · Revenue $80.34B · 1 analysts
Est. EPS $11.67 · Revenue $85.26B · 1 analysts
Est. EPS $12.33 · Revenue $87.86B · 1 analysts
Est. EPS $42.85 · Revenue $347.58B · 2 analysts
$8.00 per share
$8.00 per share
EPS INR 5.35 · Revenue INR 81.18B
EPS INR 53.92 · Revenue INR 353.47B
EPS INR 14.52 · Revenue INR 87.27B
EPS INR 17.25 · Revenue INR 88.05B
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $353.5B | +8.6% | +6.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $45.1B | -20.3% | +99.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +52.8% | -9.8% | +3.8% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +13.8% | -37.4% | +490.4% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +12.8% | -26.6% | +87.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $32.1B | +166.8% | -143.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +9.1% | +145.8% | -140.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 20.5% | +46.2% | -8.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.80x | -6.0% | +5.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $567.9B | +15.2% | +1.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 53.92 vs 60.13 | -10.3% | 5.35 vs 8.75 | -38.8% |
| Revenue Surprise | $353.5B vs $345.1B | +2.4% | $81.2B vs $81.0B | +0.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | MUNNIRPALLAM MADHU SUNDAR SUBRAMANIAN | officer: Global Head of Quality and PV | Equity Shares | — | 0 | — |
| Dec 18, 2025 | AGHANIAN PATRICK RUDOLF | officer: Head - Europe Generics | Equity Shares underlying ADRs | — | 0 | — |
| Dec 18, 2025 | KALAWADIA MILAN KANTILAL | officer: CEO - North America | Equity Shares underlying ADRs | — | 0 | — |
| Dec 18, 2025 | MOTUPALLI VENKATA RAMANA | officer: CEO - Global Generics | Equity Shares | — | 0 | — |
| Dec 18, 2025 | Israeli Erez | officer | — | — | 0 | — |
Aishwarya Sitharam: Joining us today are Erez Israeli and M. V. Narasimham. Our quarterly financial results have been published earlier today and are available on our website for your reference. We will start today's call with MVN providing an overview of our financial performance for the quarter. Following that, Erez will share his insights on key business highlights, as well as the company's strategic outlook. We will then open the floor for questions. All commentary and analysis during this call are based on our IFRS consolidated financial statements. Please note that certain non-GAAP financial measures may also be discussed. Reconciliation to the corresponding GAAP measures are included in our press release. I would like to remind everyone that the safe harbor provisions outlined in our press release today apply to all forward-looking statements made during this call. Before we proceed, I would like to call out a few housekeeping points. All participants will be in listen-only mode during the opening remarks. Should you need any technical assistance during the call, please use the chat function on your Zoom application. The chat will not be monitored for any questions to the management. The session is being recorded, and both the recording as well as the transcript will be made available on our website shortly. Please note that this call is the proprietary material of Dr. Reddy's Laboratories Limited and may not be rebroadcast or quoted in any media or public forum without prior written consent from the company. With that, let me hand the call over to MVN to present the financial highlights for the quarter. Over to you, MVN. M. V. Narasimham: Thank you, Aishwarya. Greetings to everyone on the call. It is my pleasure to walk you through our financial performance for the first quarter of FY 2027. The business reported revenue decline of 5.6% and EBITDA margin of 12.5% for the quarter, reflecting the impact of lower lenalidomide revenues, which contributed to the corresponding period last year, as well as a provision of INR 240 crores for inventory and other costs associated with the recent semaglutide API-related challenges. Notably, the underlying base business, excluding lenalidomide, continued to deliver healthy double-digit growth across all key geographies, including North America, supported by new product launches and favorable currency movements. All financial figures in this section are translated into U.S. dollars using a convenience translation rate of INR 94.66, the exchange rate prevailing as of June 30th, 2026. Consolidated revenue stood at INR 8,071 crores, which is $853 million, a decline of 5.6% year-over-year, and a growth of 7.4% on a sequential basis. Strong performance across key markets, further aided by favorable Forex, was offset by lower lenalidomide sales. NRT revenues declined primarily due to change in operating model post-integration, under which rebates and discounts are offered to distributors and recognized net …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Gunupati Venkateswara Prasad | Co-Chairman, MD & Member of Management Council | INR 1,657,463 | Male | 1960 | Active |
Kallam Satish Reddy | Chairman of the Board & Member of the Management Council | INR 1,054,816 | Male | 1967 | Active |
Bhethanabottla S. Phanimitra | Chief Digital and Information Officer & Member of the Management Council | — | Male | 1980 | Active |
Milan Kalawadia | Chief Executive Officer of North America & Member of Management Council | — | Male | 1977 | Active |
Sanjay Sharma | Executive VP, COO & Member of Management Council | — | Male | 1968 | Active |
Deepak Sapra | Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council | — | Male | 1975 | Active |
Erez Israeli | Chief Executive Officer & Member of the Management Council | — | Male | 1968 | Active |
Krishna K. Venkatesh B.Pharma | Global Head of IPDO, Integrated Product Development & Member of the Management Council | — | Male | 1973 | Active |
Mannam Venkatanarasimham | Chief Financial Officer & Member of the Management Council | — | Male | 1970 | Active |
Motupalli Venkata Ramana | CEO of Global Generics & Member of Management Council | — | Male | 1969 | Active |
Patrick Aghanian | Head of Consumer Health Organization & Member of Management Council | — | Male | 1965 | Active |
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happ.
Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (âDr. Reddy'sâ or the âCompanyâ) (NYSE: [url="]RDY[/url]
